Workflow
伟思医疗(688580) - 2025 Q1 - 季度财报
VISHEEVISHEE(SH:688580)2025-04-24 14:25

Financial Performance - The company's operating revenue for Q1 2025 was CNY 95,912,701.63, representing a year-on-year increase of 9.40% compared to CNY 87,670,336.46 in the same period last year[4] - Net profit attributable to shareholders for the same period was CNY 33,220,075.05, a significant increase of 52.71% from CNY 21,753,153.33 in the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 30,538,332.03, reflecting a year-on-year growth of 58.96%[4] - Basic earnings per share for the period were CNY 0.3472, up 52.08% from CNY 0.2283 in the same period last year[4] - Total operating revenue for Q1 2025 reached ¥95,912,701.63, an increase of 9.3% compared to ¥87,670,336.46 in Q1 2024[17] - Net profit for Q1 2025 was ¥33,220,075.05, representing a significant increase of 52.9% from ¥21,753,153.33 in Q1 2024[18] - Earnings per share (EPS) for Q1 2025 was ¥0.3472, compared to ¥0.2283 in Q1 2024, reflecting a growth of 52.2%[19] - The total comprehensive income for Q1 2025 was ¥33,220,075.05, up from ¥21,753,153.33 in Q1 2024[19] Cash Flow - The net cash flow from operating activities reached CNY 22,402,640.36, marking a substantial increase of 138.68% compared to CNY 9,386,067.11 in the previous year[4] - Cash flow from operating activities generated a net amount of ¥22,402,640.36, a substantial increase from ¥9,386,067.11 in the previous year[22] - Cash inflow from investment activities totaled ¥794,277,213.51, compared to ¥275,133,776.46 in Q1 2024[22] - Cash outflow from investment activities was ¥825,866,799.39, leading to a net cash flow from investment activities of -¥31,589,585.88[22] - The beginning cash and cash equivalents balance was $1,067,206,832.73, compared to $1,153,801,027.71 in the previous period[23] - The ending cash and cash equivalents balance was $1,058,019,311.52, down from $1,112,314,830.54 in the previous period[23] Research and Development - Total R&D expenditure was CNY 12,238,776.10, which is a decrease of 35.08% compared to CNY 18,851,562.73 in the previous year[4] - The proportion of R&D expenditure to operating revenue decreased to 12.76%, down 8.74 percentage points from 21.50% in the previous year[5] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,815,959,275.03, a slight decrease of 0.24% from CNY 1,820,364,713.20 at the end of the previous year[5] - The company's current assets totaled ¥1,155,426,317.71, down from ¥1,163,272,383.49 at the end of 2024, indicating a decrease of approximately 0.9%[14] - Cash and cash equivalents were reported at ¥1,059,037,112.46, a decrease from ¥1,068,159,804.95, reflecting a decline of about 0.1%[13] - Accounts receivable decreased to ¥23,388,812.25 from ¥25,152,299.37, representing a decline of approximately 7%[13] - Inventory decreased to ¥36,298,586.40 from ¥38,737,651.18, indicating a reduction of about 6.3%[14] - Total liabilities decreased to ¥153,858,172.25 from ¥192,901,823.87, showing a significant reduction of approximately 20.3%[15] - The company's equity capital remained stable at ¥95,771,288.00, unchanged from the previous period[15] - The company reported a decrease in accounts payable from ¥19,404,406.21 to ¥14,466,093.63, a decline of about 25.5%[15] - The total non-current assets increased slightly to ¥660,532,957.32 from ¥657,092,329.71, reflecting a growth of approximately 0.7%[14] - The company's total equity attributable to shareholders reached ¥1,662,101,102.78, an increase from ¥1,627,462,889.33 year-over-year[16] - The total liabilities and equity amounted to ¥1,815,959,275.03, slightly down from ¥1,820,364,713.20 in the previous year[16] Shareholder Information - The company reported a total of 5,933 common shareholders at the end of the reporting period[10] - The company has not reported any significant changes in shareholder relationships or actions during the reporting period[12] Accounting Standards - The company will not apply the new accounting standards or interpretations starting from 2025[23]